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Abstract
Phosphorylation is an important post-translational modification that is involved in regulating many 
signaling pathways. Of particular interest are the growth factor mediated Ras and phosphoinositide 
3-kinase (PI3K) signaling pathways which, if misregulated, can contribute to the progression of 
cancer. Phosphoproteomic methods have been developed to study regulation of signaling 
pathways; however, due to the low stoichiometry of phosphorylation, understanding these 
pathways is still a challenge. In this study, we have developed a multi-dimensional method 
incorporating electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) with 
tandem IMAC-TiO2 enrichment for subsequent phosphopeptide identification by LC/MS/MS. We 
applied this method to PDGF-stimulated NIH 3T3 cells to provide over 11,000 unique 
phosphopeptide identifications. Upon motif analysis, IMAC was found to enrich for basophilic 
kinase substrates while the subsequent TiO2 step enriched for acidophilic kinase substrates, 
suggesting that both enrichment methods are necessary to capture the full complement of kinase 
substrates. Biological functions that were over-represented at each PDGF stimulation time point, 
together with the phosphorylation dynamics of several phosphopeptides containing known kinase 
phosphorylation sites illustrate the feasibility of this approach in quantitative phosphoproteomic 
studies.
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1. Introduction
Protein phosphorylation is among the most widespread post-translational modification 
(PTM) affecting almost every cellular process, including signal transduction pathways that 
are involved in cell proliferation, survival and differentiation. Understanding how these 
signaling pathways are controlled is important since misregulation contributes to the 
progression of cancer [1–3]. Traditionally, the phosphorylation dynamics of proteins 
involved in these signal transduction pathways have been elucidated using quantitative 
immunoblotting and other antibody-based methods [4–9]. More recently, global 
phosphoproteomic studies using LC/MS/MS have been implemented to study pathway 
regulation [10,11] and have advantages over quantitative immunoblotting such as the ability 
to multiplex and independence from the use of poorly characterized antibodies or those with 
limited specificity. However, challenges for LC/MS/MS studies including optimization of 
phosphopeptide enrichment protocols still remain.
Several phosphopeptide enrichment methods have been described which first use a liquid 
chromatography method to fractionate peptides, such as strong cation exchange (SCX) 
[12,13], strong anion exchange (SAX) [14], hydrophilic interaction chromatography 
(HILIC) [15], basic reversed-phase [16], or electrostatic repulsion-hydrophilic interaction 
chromatography (ERLIC) [17]. This fractionation is then followed by a phosphopeptide 
enrichment step [18–22]. Even though modifications to previous methods [23,24] or 
antibody-based phosphopeptide enrichment methods [25,26] have been developed, 
immobilized metal ion affinity chromatography (IMAC) [27] or TiO2 [28] affinity 
enrichment are still the most widely used in phosphoproteomic analysis. With IMAC, a 
positively charged metal cation, such as Fe3+, Zr4+ or Ga3+, chelated to a solid-phase 
support noncovalently binds to a negatively charged phosphate group at low pH. While non-
specific binding is minimized by washing with a low pH solution prior to phosphopeptide 
elution, non-specific binding of acidic peptides hinders this enrichment process. TiO2 is a 
type of metal oxide affinity chromatography that has been shown to enrich for 
phosphopeptides more efficiently and with better selectivity than IMAC. This is 
accomplished by using various organic acids, such as 2,5-dihydroxybenzoic acid (DHB) and 
glycolic acid, to block binding of acidic peptides, leading to an increase in phosphopeptide 
specificity [28]. Differences in phosphopeptide populations enriched by IMAC and TiO2 
have been observed, especially with regards to the number of phosphorylation sites per 
peptide. IMAC enriches for multiply phosphorylated peptides more efficiently than TiO2, 
while TiO2 enriches for a higher proportion of mono-phosphorylated peptides [29,30]. 
Additionally, it has been argued that using IMAC results in under-representation of 
basophilic kinase substrates, which could lead to biases in the data and an unbalanced 
portrayal of the phosphoproteome [24]. The analytical merit of implementing both of these 
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enrichment methods, either individually or sequentially, to increase the number and variety 
of identified phosphopeptides has been demonstrated [29–33].
Previously we reported a method for phosphopeptide enrichment incorporating ERLIC 
fractionation with IMAC [34]. Using this as a basis, we optimized a multi-dimensional 
method using ERLIC fractionation coupled with a tandem IMAC and TiO2 enrichment 
approach in order to take advantage of characteristics of both of these phosphopeptide 
enrichment strategies. The method was applied to PDGF responsive NIH 3T3 cells over a 
120 min time course, followed by LC/MS/MS analysis using a data-dependent CID/ETD 
decision tree (DT) method. We demonstrated the capability of this approach to enrich for a 
wide variety of phosphopeptides pertaining to both basophilic and acidophilic kinase 
substrate motifs when compared to other methods evaluated in this study. Furthermore, the 
analysis of biological functions that were over-represented at each time point, as well as the 
phosphorylation dynamics of several phosphopeptides illustrated the feasibility of our 
method for use in future quantitative studies.
2. Materials and Methods
2.1 Materials
All tissue culture reagents were purchased from Invitrogen (Life Technologies, 
www.lifetechnologies.com). Human recombinant PDGF-BB was purchased from Peprotech 
(www.peprotech.com). NIH 3T3 mouse fibroblasts were obtained from American Type 
Culture Collection (www.atcc.org). Acetonitrile (HPLC grade) and formic acid (ACS 
reagent grade) were from Sigma-Aldrich (www.sigmaaldrich.com). Acetone was purchased 
from Thermo Fisher Scientific (www.thermofisher.com). Ammonium bicarbonate and 
guanidinium chloride were from Fluka (www.sigmaaldrich.com). Water was distilled and 
purified using a High-Q 103S water purification system (www.high-q.com). All other 
reagents and chemicals were purchased from Sigma-Aldrich-Fluka unless otherwise stated.
2.2 Cell Culture and Lysis
NIH 3T3 fibroblasts were cultured at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, and the antibiotics 
penicillin (100 units/ml) and streptomycin sulfate (100 µg/ml). Dishes to be processed on the 
same day were plated with equal numbers of cells and allowed to reach 90% confluency. 
Cells were serum-starved for 3 h prior to no stimulation or 300 pM PDGF stimulation for 15 
or 120 min. Cells were harvested and lysed as previously described [4]. A 5-fold volume of 
ice-cold acetone was added to each sample, vortexed, and then incubated at −20°C 
overnight. After centrifugation, the supernatant was discarded and the dried protein 
precipitate was dissolved in 50 mM ammonium bicarbonate (pH 8.2) containing 8 M urea. 
The total protein concentration was determined by the BCA assay (Pierce, 
www.piercenet.com).
2.3 Protein Digestion
Equal amounts of protein from each sample were reduced with 5 mM DTT at 56°C for 30 
min and alkylated with 15 mM iodoacetamide in the dark at room temperature for 1 h. The 
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samples were diluted 1:8 with 50 mM ammonium bicarbonate and digested with sequencing 
grade trypsin (Promega, www.promega.com) at a 1:100 trypsin:protein ratio overnight at 
37°C. Peptides were desalted using a Grace Prevail C18 solid-phase extraction cartridge, 
and the solvent was evaporated via vacuum centrifugation. Peptides were stored at −80°C 
until further processing.
2.4 ERLIC Fractionation
Each ERLIC separation was performed on an Agilent 1100 series HPLC system using a 4.6 
× 200 mm, 5 µm particle size, 300A pore size PolyWAX LP column (PolyLC, Inc; 
www.polylc.com), as we previously described [34] with slight modifications. Briefly, the 
mobile phase consisted of (A) 20 mM ammonium formate, pH 2.2/70% acetonitrile (ACN) 
and (B) 300 mM ammonium formate, pH 2.2/20% ACN. After injection, an isocratic flow of 
15 min at 100% A was followed by a linear gradient from 0–50% B over 20 min and a linear 
gradient of 50–100% B over 5 min at a flow rate of 0.75 ml/min. Fractions were collected 
every minute and then combined into five total fractions based on chromatographic peak 
intensities measured at 280 nm using a diode array detector. Each sample was dried under 
vacuum centrifugation and stored at −20°C until phosphopeptide enrichment.
2.5 Phosphopeptide Enrichment
The procedure for IMAC (Fe-IMAC) was as we previously described [34], with a few 
modifications. Briefly, nitriloacetic acid (NTA) resin (Life Technologies, 
www.lifetechnologies.com/) charged with 100 mM FeCl3 was packed into a gel loading 
pipet tip made in-house containing a frit, and the resin was washed twice with 100 µl of 2% 
acetic acid. ERLIC fractionated peptides were resolubilized in 2% acetic acid, loaded onto 
the IMAC column, and washed twice with 100 µl of 2% acetic acid. The flow through and 
washes were collected and dried using vacuum centrifugation. A more stringent wash was 
performed twice with 100 µl of 74/25/1 100 mM NaCl/ACN/acetic acid (v/v/v), followed by 
a 100 µl wash with only water. Retained peptides were eluted with 100 µl of 5% NH4OH, 
then immediately acidified to pH 3 with formic acid. The eluted peptides were dried using 
vacuum centrifugation, and resuspended in 0.1% formic acid for LC/MS/MS analysis. This 
fraction is referred to as the “IMAC fraction”.
The IMAC flow through and washes were subjected to TiO2 enrichment using the Protea 
TiO2 SpinTips Sample Prep Kit (proteabio.com) following manufacturer’s instructions. 
Briefly, 4 mg of TiO2 material was used for each sample and was washed two times with 
100 µl of wash solution 1. Peptides were loaded on the TiO2 column and washed two times 
with 100 µl of wash solution 1, followed by two more washes with 100 µl of wash solution 
2. Retained peptides were eluted with the elution solution. The eluted peptides from TiO2 
were acidified to pH 3 with formic acid, dried using vacuum centrifugation, and resuspended 
in 0.1% formic acid for LC/MS/MS analysis. This fraction is referred to as the “IMAC-TiO2 
fraction”. The entire sample preparation workflow is illustrated in Figure 1.
2.6 LC/MS/MS Data Acquisition
LC/MS/MS analyses were performed on an Easy nLC 1000 ultra-pressure liquid 
chromatograph coupled to an ETD equipped LTQ Orbitrap Elite mass spectrometer (Thermo 
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Scientific, www.thermoscientific.com). Samples were injected onto a PepMap C18, 5 µm, 
trapping column (Thermo Scientific) then separated by in-line gradient elution onto a New 
Objective (www.newobjective.com) Self-Pack PicoFrit column (75 µm id × 15 cm) packed 
in-house with 1.7 µm BEH C18 stationary phase (Waters Corporation, www.waters.com). 
The linear gradient for separation consisted of 5–40% mobile phase B over 60 min at a 300 
nl/min flow rate, where mobile phase A was 0.1% formic acid/2% ACN in water and mobile 
phase B consisted of 0.1% formic acid in ACN. The Orbitrap Elite was operated in data-
dependent decision tree mode [35] where the 15 most intense precursors were selected for 
subsequent fragmentation using optimal settings for each activation technique (illustrated in 
Supplementary Figure S1). Resolution for the precursor scan (m/z 400–2000) was set to 
60,000 at m/z 400 with a target value of 1×106 ions. The MS/MS scans were acquired in the 
linear ion trap with a target value of 5000. The normalized collision energy was set to 35% 
for CID. For ETD, reaction time was set to 50 ms and supplemental activation using CID 
was enabled. The signal intensity threshold for triggering an MS/MS event was set to 1000. 
For internal mass calibration, the ion of polycyclodimethylsiloxane with m/z 445.120025 
was used as the lock mass [36]. Monoisotopic precursor selection was enabled, and 
precursors with unknown charge or a charge state of 1 were excluded.
2.7 Data Analysis
Raw data files of the IMAC and IMAC-TiO2 fractions were processed using Proteome 
Discoverer (PD) version 1.3 (Thermo Scientific). The non-fragment filter was used to 
simplify ETD spectra to remove unfragmented precursor or charge-reduced precursor peaks. 
Peak lists were searched against a forward and reverse Mus musculus UniProt database 
(74232 sequences) using both Mascot (Matrix Science) and Sequest (Thermo Scientific). 
The following parameters were used to identify tryptic peptides for protein identification: 10 
ppm precursor ion mass tolerance; 0.6 Da product ion mass tolerance; up to two missed 
trypsin cleavage sites; carbamidomethylation of Cys was set as a fixed modification; 
oxidation of Met and phosphorylation of Ser, Thr, and Tyr were set as variable 
modifications. The percolator node was used to estimate the number of false positive 
identifications, and a q-value was assigned; a “high confidence” q-value of <0.01 was used 
to filter all results. The phosphoRS algorithm was used to measure the phosphorylation site 
localization probabilities [37]. Only phosphopeptides with pRS probabilities above 70% 
were considered for phosphorylation motif analyses, which were conducted using motif-x 
[38,39]. Motif-x default settings were used (with the MS/MS IPI Mouse Proteome as 
foreground format and as background), except the significance threshold was set to a more 
stringent value of 1×10−7 to reduce false positives. For relative quantification of specific 
phosphopeptides, peaks areas for each identified phosphopeptide were extracted using the 
peak area node in PD.
2.8 Bioinformatics Analysis
All analyses were conducted using either JMP Pro 10.0 (SAS Institute, www.sas.com) or 
Microsoft Excel 2010. The ClueGo plug-in [40] within Cytoscape [41] (version 3.0.2) was 
used to determine over-represented molecular function GO annotations and KEGG 
pathways. Enrichment analysis was based on two-sided minimal-likelihood test on the 
hypergeometric distribution. The Bonferroni step down correction was employed to adjust 
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p-values for statistically enriched terms (p-value of 0.1 was considered significant). Venn 
diagrams were generated using the Venn Diagram Plotter (PNNL, omics.pnl.gov).
3. Results and Discussion
3.1 Development of a tandem phosphopeptide enrichment strategy combining ERLIC, 
IMAC and TiO2 with CID/ETD LC/MS/MS analysis
The aim of this study was to develop an optimal phosphopeptide enrichment strategy to 
detect phosphorylation events occurring in PDGF-stimulated fibroblasts using mass 
spectrometry. In order to reduce sample complexity and increase the ability to identify 
phosphopeptides, we coupled ERLIC with tandem IMAC/TiO2 enrichment. ERLIC was 
chosen for off-line LC peptide separation since it is a combination of hydrophilic interaction 
and weak anion-exchange that favors retention and separation of relatively hydrophilic, 
negatively charged analytes such as phosphopeptides [17]. Previous studies using only 
ERLIC have demonstrated an enrichment of phosphopeptides [42,43]. To test this with our 
system, we analyzed several ERLIC fractions by LC/MS/MS and detected very few 
phosphopeptides (data not shown), which has also been reported in the literature [34,44]; 
therefore, an enrichment step after ERLIC fractionation was required.
Frequently after any type of off-line LC separation of peptides, the phosphopeptides are 
enriched using IMAC or TiO2. The capacity of the IMAC or TiO2 material can be estimated, 
but regardless of this, some phosphopeptides will have limited binding due to the low 
phosphorylation stoichiometry, as well as competition with other phosphopeptides and 
acidic peptides, thus precluding their identification. In order to enrich for phosphopeptides 
that may have not been captured when only implementing a single enrichment strategy and 
eventually end up in the flow-through/wash portion of the sample, a tandem phosphopeptide 
enrichment approach was developed. By retaining the flow-through/wash generated by one 
phosphopeptide enrichment method and subjecting it to a different enrichment method, it is 
possible to maximize the number of unique phosphopeptides identified [30].
In this study, a combination of IMAC (Fe-IMAC) and TiO2 was chosen in order to take 
advantage of both phosphopeptide enrichment methods. Our order of phosphopeptide 
enrichment by IMAC and TiO2 was experimentally determined by comparing the 
enrichment of unstimulated NIH 3T3 cell lysate digest (200 µg) using IMAC first, followed 
by TiO2 enrichment of the IMAC flow-through/wash (the IMAC-TiO2 sample) versus 
enriching the same amount of NIH 3T3 cell lysate digest with TiO2 first, then using IMAC 
on the TiO2 flow-through/wash (the TiO2-IMAC sample). As shown in Supplementary 
Figure S2, using IMAC or TiO2 first enriched for about the same number of 
phosphopeptides, but the enrichment percentage was lower for IMAC (45%) when 
compared to TiO2 (80%), thus indicating that a higher level of non-specific binding was 
occurring with IMAC. For the second enrichment step, the IMAC-TiO2 fraction produced 
more identified unique phosphopeptides than the TiO2-IMAC fraction; therefore, the tandem 
enrichment order of IMAC followed by TiO2 was used for our study. It should be noted that 
the IMAC-TiO2 flow-through/wash was also analyzed, but only 44 phosphopeptides out of 
4059 total peptides (1% enrichment) were identified, and thus it was excluded from 
subsequent analyses.
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For our study, NIH 3T3 cells were stimulated with PDGF for 0, 15 and 120 min then lysed 
and digested with trypsin. Each lysate digest (3 mg for each time point) was separated using 
ERLIC to produce a total of five fractions, which were subsequently enriched for 
phosphopeptides with our optimized tandem IMAC/TiO2 method (Figure 1). Although the 
number of ERLIC fractions was less than the typical 10 to 25 fractions generated by ERLIC 
or SCX for off-line peptide separations [19,22,42], the number of fractions doubles to 10 per 
stimulation time point (30 samples total) since each ERLIC fraction was subjected to tandem 
IMAC/TiO2 enrichment. Therefore, minimizing the number of ERLIC fractions helped to 
reduce sample preparation and LC/MS/MS acquisition time. The list of unique 
phosphopeptides for all ERLIC fractions and subsequent affinity enrichment steps is 
presented in Supplementary Table S1.
To better identify phosphopeptides during LC/MS/MS, a data dependent DT acquisition 
method utilizing CID and ETD was evaluated (Supplementary Figure S3A) and 
implemented. After data processing, 11,310 unique phosphopeptides were identified across 
all 30 samples. The phosphopeptides targeted for ETD fragmentation resulted in slightly 
higher phosphorylation site localization probabilities (pRS probabilities) compared to 
phosphopeptides targeted for CID fragmentation (Supplementary Figure S3B) and about 9% 
of phosphorylated peptides were uniquely identified using ETD (Supplementary Figure 
S3C).
3.2 Enhanced phosphopeptide detection in NIH 3T3 cells using a tandem IMAC/TiO2 
enrichment approach
To evaluate the phosphopeptide enrichment strategies, all five ERLIC fractions 
corresponding to IMAC and IMAC-TiO2 enrichment at each time point of PDGF 
stimulation were examined. A similar phosphopeptide distribution in ERLIC fractions 
among each corresponding IMAC and IMAC-TiO2 sample was observed across the time 
course (Figure 2A). For ERLIC Fractions 1–4, a disproportionate number of 
phosphopeptides were enriched by IMAC compared to IMAC-TiO2 with an exception 
occurring at ERLIC Fraction 2 at 15 min. However, for ERLIC Fraction 5 across all time 
points, the number of phosphopeptides enriched by IMAC-TiO2 was dramatically higher 
than IMAC enrichment and is in stark contrast to the other four ERLIC fractions. The 
consistency in the level of phosphopeptide enrichment between IMAC and IMAC-TiO2 
across all time points indicates that this method is robust among ERLIC fractionated 
unstimulated and stimulated samples.
These observations can be explained when considering the nature of the ERLIC separation. 
During ERLIC, the gradient linearly increases from 20 to 300 mM ammonium formate, thus 
the highly acidic or multiply phosphorylated peptides elute later in the gradient and is best 
represented by ERLIC Fraction 5. The population of phosphopeptides detected in this 
fraction suggests that IMAC is less effective at enriching for acidic and/or multiply 
phosphorylated peptides than the subsequent TiO2 step. To determine if non-specific 
binding of acidic peptides was the cause of this decrease in IMAC-enriched 
phosphopeptides, the non-phosphorylated peptides were examined. In ERLIC fraction 5, the 
number of non-phosphorylated peptides was low for both IMAC and IMAC-TiO2 samples, 
Herring et al. Page 7













suggesting that IMAC was not enriching for highly acidic non-phosphorylated peptides at 
the expense of phosphopeptides. This decrease in IMAC-enriched phosphopeptides in later 
ERLIC fractions has been observed previously [34].
When considering all unique 11,310 phosphopeptides identified, only 23% were identified 
in both the IMAC and IMAC-TiO2 fractions with more unique phosphopeptides identified in 
the IMAC fractions (46%) compared to the IMAC-TiO2 fractions (31%) (Figure 2B). This 
relatively low overlap suggests that using a tandem IMAC/TiO2 enrichment strategy yields 
more unique phosphopeptide identifications as opposed to using only IMAC or TiO2 after 
the ERLIC separation. It is interesting to note that the general characteristics of the 
phosphopeptide populations enriched by either IMAC or IMAC-TiO2 are different: (1) 
longer phosphopeptides were enriched in the IMAC-TiO2 fractions compared to IMAC 
fractions and (2) the overall pI of the phosphopeptide population in the IMAC-TiO2 
fractions was lower (average pI of 4.6) than the IMAC fractions (average pI of 6).
When considering the subgroup of multiply phosphorylated peptides (Figure 3A), IMAC-
TiO2 enriched for multiply phosphorylated peptides slightly more efficiently than IMAC on 
the basis of enrichment percentage (17% compared to 13%), but both enrichments produced 
nearly the same number of unique multiply phosphorylated peptides. A closer examination 
of individual ERLIC fractions reveals that for ERLIC Fractions 1–4, IMAC enriched for a 
greater number and higher percentage of multiply phosphorylated peptides (Figure 3B) 
compared to IMAC-TiO2 (Figure 3C); however, for ERLIC Fraction 5, IMAC-TiO2 is 
vastly superior to IMAC. Considering that 74% of all multiply phosphorylated peptides 
identified by IMAC-TiO2 were in ERLIC Fraction 5, it can be concluded that IMAC-TiO2 is 
able to enrich for larger, highly acidic multiply phosphorylated peptides better than IMAC. 
Overall, these data suggest that there is complementarity between the IMAC and IMAC-
TiO2 phosphopeptide enrichment methods as applied to ERLIC separated peptide fractions.
3.3 IMAC and IMAC-TiO2 enrich for different phosphorylation motifs
Although the tandem affinity enrichment of IMAC and IMAC-TiO2 of ERLIC fractionated 
peptides appear to favor basic and acidic phosphopeptides, respectively, the overall ratio of 
pS:pT:pY between these two enriched fractions was very similar: 84:14:2 and 87:12:1, 
respectively. In order to provide a more definitive comparison to assess the basic and acidic 
phosphopeptide preferences between the two enrichment methods, phosphorylation motif 
analysis was conducted using motif-x [38,39].
As shown in Figure 4A, IMAC and IMAC-TiO2 enrich for noticeably different pS motifs. 
The top pS motifs for the IMAC fractions were those with an overall neutral or positive 
charge, while the top motifs for the IMAC-TiO2 fractions were those with an overall 
negative charge. These results clearly indicate that the enrichment of ERLIC fractionated 
peptides: IMAC-TiO2 is better at enriching for acidic phosphopeptides than IMAC. For pT 
motifs (Figure 4B), IMAC and IMAC-TiO2 were able to enrich for very similar proline-
directed kinase motifs. Motif-x analysis was also conducted for pY motifs, but the low 
number of phosphopeptides (~100) used in the search precluded the identification of any 
motifs. To better understand these findings, the biological significance of the identified 
kinase motifs was examined.
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Many of the kinase motifs enriched by our ERLIC-based tandem IMAC/TiO2 affinity 
approach have been biologically well-characterized. The RRxpS motif is found in basophilic 
substrates that are phosphorylated by Arg-directed or AGC-family kinases, such as PKA, 
PKG, PKC, RSK and Akt, which all play important roles in signal transduction [45]. The 
(pS/T)PxK/R motifs are found in MAPK/CDK substrates, which are involved in cell 
proliferation and cell cycle control [46]. Some substrates for Akt, which plays a role in 
mediating critical cellular responses, are known to contain the RxRxxpS/T motif [47]. The 
pS motifs such as pS(D/E)xE and pSxDxExE, are found in acidophilic substrates 
phosphorylated by CK2. CK2 is a highly conserved, ubiquitous, and constitutively active 
Ser/Thr protein kinase with hundreds of targets that are involved in a variety of cellular 
processes such as cell cycle progression, apoptosis, transcription, inflammation, and DNA 
damage response [46,48]. It is widely known that the majority of peptides are 
phosphorylated by proline-directed kinases [38,49], thus are probably highly abundant 
relative to some other motifs. Two of these ubiquitous motifs (RxxpSP and pSPxK) were 
found in both IMAC and IMAC-TiO2 samples suggesting that the amount of IMAC resin 
used may not provide the necessary binding capacity to enrich for all phosphopeptides 
containing these motifs, and thus those not completely retained are further captured by 
subsequent TiO2 affinity.
A previous study also found that TiO2 has a tendency to isolate acidic phosphopeptides 
when compared to IMAC without any prior fractionation step [29] while another study 
found no bias in phosphopeptides enriched from complex peptide mixtures by IMAC and 
TiO2 [50]. To determine if the motif selectivity we observed was a result of ERLIC 
fractionation, motif-x analysis was conducted for LC/MS/MS identified peptides enriched 
from an unstimulated NIH 3T3 cell lysate using only IMAC or TiO2 enrichment. An almost 
identical mixture of both acidophilic and basophilic kinase substrate motifs were identified 
between the IMAC and TiO2 samples (Supplementary Figure S4), indicating that not as 
many unique motifs were identified if only IMAC or TiO2 enrichment were performed 
without prior ERLIC fractionation. Interestingly, if an additional enrichment step using 
either TiO2 on the IMAC flow-through/wash or IMAC on the TiO2 flow-through/wash was 
performed, enrichment of only motifs associated with basophilic kinase substrates was 
observed These data indicate that a significant enrichment of motifs associated with 
acidophilic kinase substrates occurs only if ERLIC fractionation is used prior to IMAC/TiO2 
tandem enrichment. In comparison to a previous study [42], ERLIC alone produced better 
coverage of acidophilic kinase substrates compared to SCX/IMAC, but SCX/IMAC 
produced better coverage of basophilic kinase substrates, which is consistent with the 
chemical basis of the separation prior to IMAC. Overall, these findings suggest that our 
method of combining ERLIC with IMAC/TiO2 tandem affinity increases the 
phosphopeptide enrichment efficiency of both acidophilic and basophilic kinase substrates.
3.4 Biological Effects upon PDGF Stimulation Time Course
To obtain a better understanding of the signaling pathways modulated by PDGF stimulation, 
the Cytoscape plugin, ClueGO, was used to determine the over-represented KEGG pathways 
within the total phosphoproteomic dataset (Figure 5). The pathways of interest, which 
include the well-characterized MAPK, Ras, and the PI3K-Akt pathways, were significantly 
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represented in the dataset. Intriguingly, the mTOR pathway, which is known to be involved 
in crosstalk with the PI3K-Akt and Ras pathways [51–53], was the most over-represented 
pathway in the dataset. Other interesting over-represented pathways include the cell cycle, 
focal adhesion signaling, and the p53 pathway. Several of the detected phosphorylation sites 
within proteins involved in these pathways are of unknown function (e.g., Ser198 on Rin1) 
or are completely novel sites (e.g., Ser1000 on Abl2), suggesting the possibility of novel 
regulatory features within the PDGF signaling network.
In terms of overall phosphorylation identification (Supplementary Figure S5), the overlap of 
phosphopeptides in all three sample sets (0, 15 and 120 min) was 21% whereas the 
phosphoprotein overlap was 45%, indicating that numerous phosphorylation events are 
occurring upon PDGF stimulation. The over-represented molecular function GO terms for 
each PDGF stimulation time point are shown in Supplementary Figure S6. It is evident that 
some functions are more prevalent during specific PDGF stimulation time points. For 
example, kinase activity and histone binding were over-represented at 15 min whereas 
cytoskeletal binding and phosphatase activity were over-represented at 120 min. Very few 
phosphoregulated functions were over-represented at 0 min, consistent with quiescent cell 
state.
To explore the data further, the phosphorylation dynamics of specific phosphopeptides 
corresponding to proteins in the Ras and PI3K signaling pathways were calculated 
(Supplementary Figure S7) and compared to previously published results. The ERK2 
phosphorylation sites pT183 and pY185 and the MEK1/2 phosphorylation site pS222 both 
displayed transient phosphorylation kinetics which are consistent with previously published 
immunoblot data [5,6]. Raf-1, which is phosphorylated by ERK1/2 at several residues 
including the identified pS642 site [54], clearly demonstrated a sustained increase in 
activation over time. A similar trend was previously observed in immunoblot analysis of 
other Raf-1 sites phosphorylated by ERK1/2 [6]. These results suggest that the 
multidimensional phosphopeptide enrichment method presented here could be a viable 
approach for future quantitative studies.
4. Conclusions
In this study, a phosphopeptide enrichment strategy that combines ERLIC and tandem 
IMAC-TiO2 enrichment was developed and applied to PDGF-stimulated NIH 3T3 cells. We 
determined that phosphopeptide enrichment using IMAC followed by TiO2 enrichment was 
the optimal order of enrichment. When applied to ERLIC fractions, the level of 
phosphopeptide enrichment was consistent between IMAC and IMAC-TiO2 across all time 
points suggesting that this method is reliable even for comparisons among unstimulated and 
stimulated samples. Furthermore, the enrichment strategy yielded a wide variety of 
phosphorylation motifs suggesting that IMAC-TiO2 tandem affinity is needed to obtain the 
full complement of kinase substrates. It should be noted that the number of phosphopeptides 
identified could vary greatly depending upon the specific IMAC (e.g., implementing metal 
ions other than Fe3+) and TiO2 materials and protocols used, tissue or cell type, and other 
sample preparation variables required for a particular study. However, the motif selectivity 
displayed should still be observed for other systems using our ERLIC/IMAC/TiO2 approach.
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Based on GO annotation, specific molecular functions were over-represented at each time 
point, indicating that PDGF stimulation induces phosphorylation changes in a variety of 
proteins, not just those in the Ras and PI3K pathways. The phosphorylation changes for a 
few well-characterized proteins were calculated, suggesting that quantitative data can be 
obtained using our current approach. Given the importance of protein phosphorylation in 
cell regulation, the ERLIC and tandem IMAC-TiO2 phosphopeptide enrichment approach 
presented here should be useful for future quantitative studies to further improve our 
understanding of signal transduction networks.
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• Developed a novel ERLIC-IMAC-TiO2 phosphoproteomic enrichment 
approach.
• Applied to PDGF-responsive cells, yielding 11,000+ phosphopeptide 
identifications.
• Identified several enrichment method-specific phosphorylation motifs.
• Many biological pathways including MAPK and mTOR were over-represented 
in the data.
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Experimental workflow. NIH 3T3 cells were stimulated with 300 pM PDGF for 0, 15, and 
120 min, then harvested. Each lysate (3 mg) was denatured, reduced, alkylated, digested 
with trypsin, then fractionated using ERLIC. Selected ERLIC fractions were pooled to 
generate five fractions per stimulation time point, and each ERLIC fraction was 
subsequently enriched for phosphopeptides using IMAC. The IMAC eluate for each fraction 
per time point was set aside, while the IMAC flow-through/wash (FT/W) was subjected to 
further phosphopeptide enrichment using TiO2. LC/MS/MS analysis of the IMAC eluate 
Herring et al. Page 15













(referred to as the IMAC fraction) and the TiO2 eluate from the IMAC FT/W (referred to as 
the IMAC-TiO2 fraction) was performed using an Orbitrap Elite system implementing 
CID/ETD decision tree (DT) acquisition analysis.
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Distribution of phosphopeptides detected in the IMAC and IMAC-TiO2 samples for PDGF-
stimulated NIH 3T3 cells. (A) Number of phosphopeptides identified in each IMAC and 
IMAC-TiO2 sample for each stimulation time point and ERLIC fraction. (B) A Venn 
diagram of unique phosphopeptides identified in the IMAC and IMAC-TiO2 samples. 
“IMAC” samples were generated by enriching each of the five ERLIC fractions using 
IMAC, and “IMAC-TiO2” samples were generated by enriching each IMAC flow-through/
wash using TiO2.
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Assessment of multiply-phosphorylated peptides. (A) Pie charts illustrating the number and 
percentage of monophosphorylated and multiply phosphorylated peptides identified in the 
IMAC and IMAC-TiO2 samples. The distribution of the percentage and number of mono- 
and multiply-phosphorylated peptides identified in each individual ERLIC fraction across all 
time points for the (B) IMAC and (C) IMAC-TiO2 fractions. “IMAC” samples were 
generated by enriching each of the five ERLIC fractions using IMAC, and “IMAC-TiO2” 
samples were generated by enriching each IMAC flow-through/wash using TiO2.
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Phosphorylation motif analyses of phosphopeptides identified in PDGF-stimulated NIH 3T3 
cells across all time points using motif-x. Phosphopeptides with at least a 70% site 
localization confidence score (pRS of 0.7) were used for motif-x analysis. Of the 11,310 
unique phosphopeptides identified in all fractions and time points, 7,145 have a pRS 
probability ≥ 0.7. The top six phosphorylation motifs generated for (A) phosphoserine (pS) 
and (B) phosphothreonine (pT) in the IMAC and IMAC-TiO2 fractions are presented (top to 
bottom) according to motif score and fold increase. “IMAC” samples were generated by 
enriching each of the five ERLIC fractions using IMAC, and “IMAC-TiO2” samples were 
generated by enriching each IMAC flow-through/wash using TiO2.
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KEGG pathway analysis of all identified phosphoproteins. The ClueGO plugin within 
Cytoscape was used to determine which KEGG pathways were over-represented in the total 
dataset. The size of the nodes reflects the statistical significance of the terms. The kappa 
score indicates the relationship between terms according to their overlapping genes and was 
set to the default of 0.4. The most representative term (based on the highest percentage of 
identified proteins per term) in a group is used as the group name. Only protein groups 
considered relevant are shown.
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